Skip to content
10-K

Annual Report

Anika Therapeutics, Inc. ANIK

0001171843-25-001486

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 6, 2025 14.18M sh
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $68.74M
Current Liabilities FY 2024 · Dec 31, 2023 $31.06M
Current Assets FY 2024 · Dec 31, 2023 $163.31M
Total Assets FY 2024 · Dec 31, 2023 $270.63M
Shares Diluted restated FY 2024 · Dec 31, 2022 14.79M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $0
Capex FY 2024 · Dec 31, 2022 $7.49M
Operating Cash Flow FY 2024 · Dec 31, 2022 $4.41M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.02
Eps Basic FY 2024 · Dec 31, 2022 −$1.02
Sga Expense restated FY 2024 · Dec 31, 2022 $51.23M
Rd Expense restated FY 2024 · Dec 31, 2022 $18.32M
Net Income FY 2024 · Dec 31, 2022 −$14.86M
Operating Income restated FY 2024 · Dec 31, 2022 $3.67M
Gross Profit restated FY 2024 · Dec 31, 2022 $73.22M
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $40.61M
Revenue restated FY 2024 · Dec 31, 2022 $113.83M
Stockholders Equity FY 2024 · Dec 31, 2021 $287.09M